Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2976940 | 0.96 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL2973039 | 0.96 | LMNA (0.46) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL5673099 | 0.95 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL2977488 | 0.86 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL2975103 | 0.84 | ALDH1A1 (0.37) | SMN1; SMN2LMNAALDH1A1KMT2ATDP1 | |
| SCHEMBL3587292 | 0.84 | ALDH1A1 (0.37) | SMN1; SMN2LMNAALDH1A1KMT2APOLB | |
| SCHEMBL3577841 | 0.83 | GSTP1 (0.35) | SMN1; SMN2LMNAALDH1A1GAAMEN1 | |
| SCHEMBL3585471 | 0.81 | ALDH1A1 (0.35) | LMNAALDH1A1KMT2APOLB | |
| SCHEMBL3575364 | 0.81 | PRMT5 (0.36) | LMNAALDH1A1KMT2APOLB | |
| SCHEMBL2977189 | 0.81 | ALDH1A1 (0.37) | LMNAALDH1A1KMT2ACYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776924-B2 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-08-17 | — | — | US | disclosed |
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256191-A1 | Nitroaniline-based alkylating agents and their use as prodrugs | IDH3A, HIF1AN, IDH1 | SMN1; SMN2 2843/4885LMNA 3875/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.